{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-078162","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2025-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.012702+00:00","generated_at":"2026-05-17T11:24:04.194804+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OptimizeRx appoints Brendan Merrell COO; expands Stelmakh, Odence-Ford, D'Silva roles","bullets":["Brendan Merrell named COO effective Aug 18, 2025; base salary $325k, target bonus 40%.","Ed Stelmakh becomes Chief Financial & Strategic Officer, adding corporate strategy to finance duties.","Marion Odence-Ford promoted to Chief Legal & Administrative Officer, adding admin oversight.","Andy D'Silva promoted to Chief Business Officer, leading FP&A, IR, and strategic planning.","Changes designed to accelerate Rule of 40 strategy (sustained growth + profitability) over 2-3 years."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-078162","json":"https://secwatch.observer/filing/0001213900-25-078162.json","markdown":"https://secwatch.observer/filing/0001213900-25-078162.md","text":"https://secwatch.observer/filing/0001213900-25-078162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/0001213900-25-078162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/ea0253741-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:24:04.194804+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}